F

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico | Haematology Department

Research site
(Unclaimed)
Location
Via Francesco Sforza, 35 Padiglione Marcora 1 Piano, Milano, Milano, Italy
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

26 of 47
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue...

Active, not recruiting
Psoriasis
Drug: Apremilast

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with ep...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Lazertinib
Drug: Amivantamab

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Carboplatin
Drug: Pemetrexed

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety o...

Enrolling
Perianal Crohns Disease
Fistulizing Crohns Disease
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo
Locations recently updated

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participan...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Biological: Nivolumab
Drug: Carboplatin

Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot.The main aim of the...

Active, not recruiting
Primary Immune Thrombocytopenia
Drug: Placebo
Drug: TAK-079

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrop...

Enrolling
Multiple System Atrophy
Drug: Placebo
Drug: TAK-341

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juven...

Enrolling
Arthritis, Juvenile
Drug: Guselkumab
Drug: Ustekinumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling
Eosinophilic Gastrointestinal Disease
Eosinophilic Gastritis
Drug: Matching Placebo
Drug: Dupilumab Dose 2

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Drug: Tadalafil 40 mg
Drug: Placebo FDC

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling
Parkinson's Disease
Drug: BIA 28-6156 60 mg
Drug: BIA 28-6156 10 mg

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Enrolling
Adult Acute Myeloid Leukemia
Drug: mocravimod
Locations recently updated

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination wi...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Iberdomide

Trial conditions

Non-Small-Cell Lung Carc... (6 trials)
Crohn Disease (5 trials)
Psoriasis (3 trials)
Atopic Dermatitis (2 trials)
Colitis (2 trials)
Dermatitis (2 trials)
Diffuse Scleroderma (2 trials)
Eczema (2 trials)
Eosinophilic Esophagitis (2 trials)
Familial Primary Pulmona... (2 trials)

And 61 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems